NCT03035188View on ClinicalTrials.gov

Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2021

Conditions
Basal Cell Carcinoma
Interventions
DRUG

Vismodegib

1 capsule (150 mg vismodegib) taken once daily for a maximum of 12 weeks.

Trial Locations (12)

10117

Charité - Universitätsmedizin Berlin, Berlin

21614

Elbe Kliniken Stade - Buxtehude GmbH, Buxtehude

48149

Universitätsklinikum Münster, Münster

48157

Fachklinik Hornheide, Münster

72076

Universitätsklinikum Tübingen, Tübingen

86179

Klinikum Augsburg Süd, Augsburg

90419

Klinikum Nürnberg Nord, Nuremberg

99089

HELIOS Klinikum Erfurt, Erfurt

07548

SRH Wald-Klinikum Gera GmbH, Gera

01307

Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden, Dresden

04103

Universitätsklinikum Leipzig, Leipzig

06484

Harzklinikum Dorothea Christiane Erxleben GmbH, Quedlinburg

All Listed Sponsors
lead

SRH Wald-Klinikum Gera GmbH

OTHER

NCT03035188 - Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma | Biotech Hunter | Biotech Hunter